Gilead made it's immuno-oncology move for Kite's CAR-T, paying $11.9 billion. GILD needs to make another move for the necessary safety augmentation that CAR-T requires for efficacy AND safety.
What's left in the tank?
Novartis already has it's CAR-T. The MSK Wolchok lab has demonstrated that anti-PS provides that needed safety when used in combination with CAR-T therapy. Will Novartis now make a move for Peregrine's anti-PS??
You do realize that big successful pharmas get that way and stay that way by buying companies whose drugs have been successful in clinical trials like KITE, not those whose drug has failed in every trial tested like PPHM, right?
Market Data 
Markets 
AI
